Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark

A Delhi court has permanently stopped Sainus Pharmaceutical Private Limited from using the 'Udaan' trademark. This ruling came after RSPL Health Private Limited filed a case alleging trademark infringement. RSPL Health, known for its 'Ghari' detergent brand, had registered its 'Udan' mark earlier. The court found Sainus Pharma's mark to be identical and deceptively similar to RSPL's registered trademark.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hBDI0m6
via IFTTT

Read More

Govt tightens rules on combinations containing 2 chemical compounds for young children

The government has restricted fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. These medicines are now prohibited for use in children below four years of age. Manufacturers must clearly display a warning on all associated product packaging. This action follows recommendations from an expert committee and the Drugs Technical Advisory Board. The notification is effective from its publication date in the official gazette.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g6Cole3
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m7sBK6b
via IFTTT

Read More

Medical devices industry needs to focus more on local value addition: Pharma Secy

The medical devices sector must increase local value addition and component manufacturing. Government officials are open to industry suggestions for PLI scheme beneficiaries. Many companies invested but could not claim incentives for various reasons. The government aims to incentivize component makers more than assembly operations. Increased domestic value addition is a key objective for the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5IK8kP
via IFTTT

Read More

Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta

The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptively similar to Dr Reddy's Labs' Daplo trademark. Both trademarks are used for prescription drugs treating Type-2 diabetes Mellitus. The court cited phonetic similarity and potential consumer confusion as key reasons. Razenta's trademark registration was cancelled within six weeks by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBO9zsi
via IFTTT

Read More

Lupin arm to commercialise YUVEZZI eye drop across key European markets

Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bm03Nq4
via IFTTT

Read More

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p51oUgc
via IFTTT

Read More